USP15 and acute myeloid leukemia: Therefore, we hypothesized that low levels of USP15 would diminish KEAP1 and lead to aberrant NRF2 activation; conversely, high expression of USP15—as observed in AML samples—would correlate with increased KEAP1 and decreased NRF2.